Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07631325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

Study acronym: MORALE-MM
StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 31, 2026 to Oct 31, 2026
    • Study description shortened, about 8 words
    • Study title shortened, about 5 words
    v3
  2. Study description expanded, about 33 wordsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
John Kirkwood
4 trials monitored
See all monitored trials
Melanoma
1,092 trials monitored
See 60 trials at risk
This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.
Trial Details
NCT Number NCT07631325
Lead Sponsor John Kirkwood
Collaborators: Glycyx MOR Inc.
Conditions
(from sponsor)		 Unresectable Cutaneous Melanoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov